ClinicalTrials.gg
CompletedNCT01221077Updated Nov 18, 2025

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

A Phase 2 interventional study of OSI-906 and Erlotinib in NSCLC and Non Small Cell Lung Cancer, sponsored by Astellas Pharma Inc. Completed at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc — 5 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Astellas Pharma Inc.

Enrollment
18th of 29
88 · median 103
Started
2011
with 1 other
Phase 2
9 of 29
none open now
Registered
13th of 29
by date

Among the 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc, this one is the 18th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 2, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Carcinoma, Non-Small-Cell Lung by Astellas Pharma Inc, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemonaive.

Read the detailed description

Based on the recommendation of the Data Monitoring Committee, OSI-906 and matching placebo are no longer being administered as of 01 March 2013.

This is a multi-center, randomized (1:1), double-blind, placebo-controlled, phase 2 study. Patients will be stratified according to the following 2 parameters: (1) EGFR activating mutation type (exon 19 deletion versus exon 21 single point mutation); and (2) Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1).

03

Conditions studied

  • NSCLC
  • Non Small Cell Lung Cancer

Keywords

  • NSCLC
  • Epidermal Growth Factor Receptor
  • EGFR
  • Non-small cell lung cancer
  • Tarceva
  • Activating mutations
  • OSI-906
  • Chemonaive
  • IGF-IR
  • Erlotinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Historically confirmed advanced NSCLC stages IIIB or IV
  • Exon 19 deletion or exon 21 activating mutation in EGFR
  • EGFR mutation status must be confirmed for participation in the study. EGFR can be performed either by central or local laboratory. If analysis is done locally, verifiable documentation confirming the EGFR mutation status must be submitted for review and approval by sponsor prior to randomization. If no local result is available, formalin-fixed, paraffin-embedded representative of the tumor or, in the absence of archival tissue, a fresh tumor tissue sample of sufficient size to perform EGFR mutation analysis must be submitted centrally. Results of the central analysis must be available prior to randomization. Additionally, subjects should provide tissue blocks for biomarker central analysis whenever possible. Ideal tissue requirement: block with ≥5 mm2 tumor area sufficient to provide four 4-micron, and five 10-micron sections
  • according to (version 1.1)
  • performance status 0-1
  • Must be able to take oral medication
  • Fasting glucose \<= 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic anti hyperglycemic therapy is permitted if the dose has been stable for >= 4 weeks at the time of randomization
  • Adequate hematopoietic, hepatic, and renal function as follows:

    • >= 1500/uL
    • count >= 100,000/uL
    • Serum creatinine \<= 1.5 x (ULN)
    • Potassium, magnesium, and calcium within normal limits (supplementation and re-testing is permitted)
    • Total \<= 1.5 x ULN
    • and ALT \<= 2.5 x ULN, or \<= 5 x ULN if patient has documented liver
  • Female subject must be either:

    • Of non child bearing potential:

      1. (defined as at least 1 year without any menses) prior to Screening, or
      2. documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening).
    • Or, if of :

      1. must have a negative urine pregnancy test at Screening, and
      2. must use two forms of (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 30 days after final study drug administration. Acceptable forms include:

        1. Established use of oral, injected or implanted hormonal methods of contraception;
        2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);
        3. Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
  • Female subject must not be breastfeeding at Screening or during the study period and for 30 days after final study drug administration.
  • Female subject must not donate ova starting at Screening and throughout the study period and for 30 days after final study drug administration.
  • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 30 days after final study drug administration. Acceptable forms include:

    1. Established use of oral, injected or implanted hormonal methods of contraception.
    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    3. Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
  • Male subjects must not donate sperm starting at Screening and throughout the study period and for at least 30 days after final study drug administration.
  • Patients must provide written to participate in the study
  • Patients may not have received chemotherapy for advanced NSCLC. Previous and/or neoadjuvant treatment for NSCLC is permitted
  • Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization. A minimum of 28 days must have elapsed between the end of radiotherapy and randomization
  • Prior surgery is permitted provided that the surgery was done >= 28 days prior to randomization and adequate wound healing has occurred prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to agents directed at the Human Epidermal Receptor (HER) axis (eg, erlotinib, gefitinib, and cetuximab)
  • Prior insulin-like growth factor -1 receptor (IGF-1R) inhibitor therapy
  • other than NSCLC within the past 3 years (exceptions if curatively treated; basal or squamous cell carcinoma of skin; locally advanced prostate cancer; ductal carcinoma in situ of breast; in situ cervical carcinoma; and superficial bladder cancer)
  • Diabetes mellitus currently requiring insulinotropic or insulin therapy
  • Use of proton pump inhibitors such as omeprazole within 14 days prior to randomization. H2-receptor antagonists such as ranitidine are not excluded
  • Symptomatic that are not stable, require , or have required radiation and/or other related treatment (i.e., anti-epileptic medication) within 21 days prior to randomization
  • Participated in any interventional clinical study or has been treated with any drugs within 30 days or 5 half lives whichever is longer, prior to the initiation of Screening or during the course of the study.
  • History of poorly controlled gastrointestinal disorders that could affect the absorption of study drug (eg, Crohn's disease or ulcerative colitis)
  • History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but no ordinary physical activity results in fatigue, palpitation, or dyspnea)
  • History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (>= grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded
  • Mean interval >= 450 msec at screening
  • Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades List' on www.azcert.org/medical-pros/drug-lists/bycategory.cfm) are prohibited within 14 days prior to randomization
  • Use of strong/moderate CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded
  • Use of strong/moderate inhibitors and inducers
  • History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability
  • History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide
  • Pregnant or breast-feeding females
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
  • Active infection, serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization), symptomatic brain metastases, or serious chronic illness that would impair the ability of the patient to receive study drug
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Arm A: Erlotinib plus OSI-906

    As of 01 March 2013, OSI-906 is no longer being administered

    Drug: OSI-906 · Drug: Erlotinib

  • Placebo comparator
    Arm B: Erlotinib plus Placebo

    As of 01 March 2013, the matching placebo is no longer being administered

    Drug: Erlotinib · Drug: Placebo

Interventions

  • As of 01 March 2013, OSI-906 is no longer being administered

  • Erlotinib administered orally

    Also known as: OSI-774, Tarceva

  • DrugPlacebo

    As of 01 March 2013, the matching placebo is no longer being administered

06

What researchers measure

Primary outcomes

  1. Progression-free survival of OSI-906 in combination with Erlotinib or Erlotinib plus placebo

    Time from randomization to disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: 15 months

Secondary outcomes

  1. Overall Survival (OS)

    Time from the date of randomization until the documented date of death.

    Time frame: 33 months

  2. Disease Control Rate (DCR)

    Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease based on RECIST version 1.1 criteria.

    Time frame: 33 months

  3. Best Overall Response Rate

    Time frame: 33 months

  4. Duration of Response (CR/PR)

    Time from the date of the first documented response (CR/PR) to documented progression or death due to underlying cancer. Defined for patients whose best overall response was CR or PR.

    Time frame: 33 months

  5. Safety assessed through evaluation of adverse events, laboratory, physical examination, and Electrocardiogram (ECG) data

    Time frame: 33 months

07

Study locations

29 sites
  • University of California, San Diego/Moores Cancer Center
    La Jolla, California 92093, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Tennessee Cancer Institute
    Memphis, Tennessee 31804, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Seattle Cancer Care Alliance University of Washington
    Seattle, Washington 98109, United States
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Regional Cancer Program
    London, Ontario N6A 4L6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Pamela Youde Nethersole Eastern Hospital
    Chai Wan, 852, Hong Kong
  • Oncocare Cancer Center
    Singapore, 258499, Singapore
  • Johns Hopkins Singapore International Medical Centre
    Singapore, 308433, Singapore
  • Chonnam National University Hwasun Hospital
    Ilsimri, Hwasun-gun 519809, South Korea
  • Asan Medical Center
    Songpa-gu, Seoul 138736, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 463-707, South Korea
  • Samsung Medical Center
    Seoul, 135710, South Korea
  • Korea University Anam Hospital
    Seoul, 136705, South Korea
  • National Cancer Institute
    Phayathai, Bangkok 10400, Thailand
  • Maharaj Nakorn Chiangmai
    Chiang Mai, 50002, Thailand
  • Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Songklanagarind Hospital, Prince of Songkla University
    Songkhla, 90110, Thailand
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in Mar 2013, 22 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2010
First posted
Oct 14, 2010
StartActual
Apr 8, 2011
Primary completionActual
Mar 1, 2013
CompletionActual
Sep 1, 2014
Results delay requested
Feb 20, 2014
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01221077
Responsible party
Sponsor
First posted
Oct 14, 2010
Start date
Apr 8, 2011
Primary completion
Mar 1, 2013
Completion
Sep 1, 2014
Last update
Nov 18, 2025

Study contacts

Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linsitinib

Start the discussion